Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              H. Lundbeck AS

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              AHS Posters for Lundbeck’s VYEPTI in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache

              Contact the Supplier

              Lead Product(s): Eptinezumab

              Therapeutic Area: Neurology Product Name: Vyepti

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 13, 2020

              Details:

              Post-hoc closed testing analysis suggests onset of a migraine preventive effect with intravenous VYEPTI as early as day 1 following the initial dose.

              H. Lundbeck AS

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI™ (eptinezumab-jjmr)

              Contact the Supplier

              Lead Product(s): Eptinezumab

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Orsini Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 22, 2020

              Details:

              Orsini Pharmaceutical has been selected as one of a very limited number of distribution partners for VYEPTI™ (eptinezumab-jjmr).

              PharmaCompass__DigitalAd